Printed on 3/17/2026
For informational purposes only. This is not medical advice.
Cholesterol ratios — particularly the total cholesterol/HDL ratio and the triglyceride/HDL ratio — are powerful predictors of cardiovascular risk that often capture risk the LDL value alone misses. This calculator computes both ratios plus non-HDL cholesterol from your standard lipid panel. The total/HDL ratio reflects the balance between all atherogenic lipoproteins and the protective HDL, with an optimal target below 3.5. The triglyceride/HDL ratio is a clinically validated surrogate marker for insulin resistance and small dense LDL particles — arguably more atherogenic than standard LDL. Cholesterol ratios are used alongside [LDL Calculator](/tools/ldl-calculator) for comprehensive lipid assessment. Elevated ratios combined with high ASCVD risk may warrant statin therapy — calculate risk with [ASCVD Risk Calculator](/tools/ascvd-risk) or [Framingham Risk Score](/tools/framingham-risk). Insulin resistance (high TG/HDL) often accompanies obesity — check [BMI Calculator](/tools/bmi-calculator).
Formula: Total/HDL Ratio = Total Cholesterol ÷ HDL | TG/HDL Ratio = Triglycerides ÷ HDL | Non-HDL = Total Cholesterol − HDL
Input total cholesterol, HDL cholesterol ('good' cholesterol), and triglycerides from your lab report. These are all measured in a standard lipid panel. Non-fasting panels are acceptable for ratio calculations — total cholesterol and HDL barely change after eating, and triglycerides rise only modestly (15-30 mg/dL on average). Fasting is preferred if triglycerides were previously very high.
Total cholesterol/HDL ratio = total cholesterol ÷ HDL. Optimal target: below 3.5 (ideal below 3.0). Triglyceride/HDL ratio = triglycerides ÷ HDL. Optimal target: below 2.0. The calculator also computes non-HDL cholesterol (total minus HDL), which captures all atherogenic particles including LDL, VLDL, IDL, and remnants.
A high total/HDL ratio (>5.0) signals increased cardiovascular risk even if LDL appears acceptable. A high TG/HDL ratio (>3.0) is a strong indicator of insulin resistance and small dense LDL particles, which are more atherogenic than standard LDL. Use these ratios with the [ASCVD Risk Calculator](/tools/ascvd-risk) or [Framingham Risk Score](/tools/framingham-risk) to guide treatment decisions.
Primary care physicians, cardiologists, patients
Check total/HDL and TG/HDL ratios at annual lipid panel review. A total/HDL ratio >5.0 or TG/HDL ratio >3.0 flags elevated cardiometabolic risk even with borderline LDL. These ratios can identify patients who warrant lifestyle intervention or statin therapy earlier. Combine with [ASCVD Risk Calculator](/tools/ascvd-risk) for guideline-based treatment thresholds.
Endocrinologists, primary care, metabolic syndrome workup
TG/HDL ratio >3.0 is a validated surrogate for insulin resistance, correlating strongly with HOMA-IR and fasting insulin. Useful when HOMA-IR testing isn't available or practical. High TG/HDL often predicts type 2 diabetes development years before fasting glucose rises. Pair with [BMI Calculator](/tools/bmi-calculator) and fasting glucose for metabolic syndrome assessment.
Patients on diet, exercise, or statin programs
Track ratios before and after starting statins, adopting a Mediterranean diet, losing weight, or increasing aerobic exercise. Total/HDL ratio improves faster than LDL alone with lifestyle changes because HDL rises while LDL falls. Recheck lipids 6-12 weeks after lifestyle changes; 4-12 weeks after starting statins.
Cardiologists, lipidologists
Identify 'residual risk' in patients on statin therapy who achieve LDL goals but maintain high TG/HDL or low HDL. Elevated non-HDL despite optimal LDL suggests VLDL/remnant-particle burden. Consider intensive lifestyle modification, adding omega-3 fatty acids for triglycerides >500 mg/dL, or PCSK9 inhibitors for persistent high non-HDL in very high-risk patients.
Patients reviewing lipid panel results
Demystify your cholesterol report. While your doctor may focus on LDL, the total/HDL ratio gives a single number indicating whether your 'good' cholesterol is keeping up with your 'bad' cholesterol. A ratio of 3.3 means for every 3.3 parts total cholesterol, one part is protective HDL — generally favorable. A ratio of 7 signals imbalance requiring attention.
Endocrinologists, primary care, preventive medicine
Metabolic syndrome diagnosis criteria include elevated triglycerides (≥150 mg/dL) AND low HDL (<40 mg/dL men, <50 mg/dL women) — the two components of the TG/HDL ratio. A TG/HDL ratio >3 is essentially synonymous with the lipid component of metabolic syndrome. Combined with waist circumference, blood pressure, and fasting glucose for full metabolic syndrome assessment.
The Framingham Heart Study found total/HDL ratio was a better predictor of myocardial infarction than LDL alone. Why? Because HDL is actively protective — it reverses cholesterol transport away from arteries. Two people with the same LDL but different HDL levels have very different cardiovascular risk. A person with LDL 130, HDL 70 (ratio 2.9) is at lower risk than someone with LDL 100, HDL 30 (ratio 7.7).
Not all LDL particles are equally dangerous. Small dense LDL particles are more atherogenic than large buoyant LDL — they penetrate the arterial wall more easily and oxidize faster. A TG/HDL ratio above 3 strongly predicts a predominance of small dense LDL (Pattern B), even when calculated LDL appears normal. This explains why some people with 'normal' LDL still develop coronary artery disease — the standard LDL test doesn't measure particle size.
Regular aerobic exercise (150+ minutes/week) raises HDL by 5-10%, lowers triglycerides by 20-30%, and reduces total cholesterol moderately. This improves both the total/HDL ratio and TG/HDL ratio — often more than dietary changes alone. High-intensity interval training (HIIT) may improve triglycerides and insulin sensitivity more than moderate-intensity steady-state cardio. Results take 8-12 weeks to show on lipid panels.
Dietary carbohydrates (especially refined carbs and added sugars) are the primary driver of elevated triglycerides. Low-carbohydrate or ketogenic diets consistently lower triglycerides by 30-50% and raise HDL by 10-20%, producing dramatic improvements in TG/HDL ratio. The Mediterranean diet (rich in olive oil, fish, nuts, and fiber) is the most evidence-backed dietary pattern for overall lipid health. Limit added sugar to <25g/day (women) or <36g/day (men).
Visceral (abdominal) fat is the primary driver of the dyslipidemic triad: high triglycerides, low HDL, and small dense LDL (manifesting as high TG/HDL ratio). Losing 5-10% of body weight lowers triglycerides by 20-40%, raises HDL by 5-15%, and improves insulin sensitivity. Even modest weight loss produces clinically meaningful ratio improvements. Calculate your BMI and target a healthy [BMI Calculator](/tools/bmi-calculator).
Moderate alcohol consumption (1 drink/day women, 2/day men) raises HDL by 5-10% — a real biochemical effect that likely contributes to the observed cardiovascular benefit. However, alcohol also raises triglycerides (especially binge drinking). Net effect on ratios depends on drinking pattern. Heavy drinking raises triglycerides dramatically, worsening TG/HDL ratio. Don't start drinking for heart health — the risks outweigh benefits.
High-intensity statins lower LDL by 50%+ but only modestly raise HDL (2-5%) and reduce triglycerides (10-20%). Despite modest effects on individual lipid fractions, the large LDL reduction significantly improves total/HDL ratio. For patients with high TG/HDL ratio despite statin therapy, adding fenofibrate (for triglycerides >500) or intensifying lifestyle changes may be warranted. PCSK9 inhibitors dramatically lower LDL but have similar modest effects on HDL and TG.
Prescription omega-3 fatty acids (icosapentaenoic acid — EPA — specifically, as in icosapent ethyl/Vascepa) at high doses (4g/day) reduce cardiovascular events in high-risk patients with elevated triglycerides despite statin therapy. The REDUCE-IT trial showed 25% reduction in MACE (major adverse cardiovascular events). This is now a Class I recommendation for patients with triglycerides >150 mg/dL on maximally tolerated statin with ASCVD or diabetes.
Non-HDL = Total cholesterol - HDL. It captures all atherogenic particles (LDL, VLDL, IDL, remnants, Lp(a)) without requiring triglycerides to be below 400 mg/dL (unlike Friedewald LDL). Target non-HDL: 30 mg/dL above your LDL goal (e.g., if LDL target is <70, non-HDL target is <100). If non-HDL is elevated despite optimal LDL, it signals high particle burden from VLDL/remnants or Lp(a).
Estrogen is protective for lipids: it raises HDL and lowers LDL. Menopause typically raises LDL by 10-20%, lowers HDL by 5-10%, and raises triglycerides — worsening all three ratios. This contributes to the acceleration of cardiovascular disease risk in women after menopause. Hormone therapy (HRT) can improve lipid ratios but must be considered in the context of individual risk/benefit. Women should have lipid panels more frequently in the perimenopausal period.
Total/HDL ratio as a superior cardiovascular predictor: Framingham Heart Study (Castelli et al., JAMA 1986; Kannel et al., Ann Intern Med 1979). TG/HDL ratio as insulin resistance surrogate: McLaughlin et al., Am J Cardiol 2005 — TG/HDL >3.0 identifies insulin resistance with sensitivity/specificity >70%. Atherogenic index of plasma: Dobiasova M, Frohlich J, Clin Chem 2001. REDUCE-IT trial (icosapent ethyl for TG >150 on statin): Bhatt et al., NEJM 2019. 2018 ACC/AHA Blood Cholesterol Guideline: Grundy et al., Circulation 2019 — non-HDL as secondary treatment target.
Your total cholesterol/HDL ratio indicates the balance between atherogenic and protective lipoproteins. A ratio below 3.5 is favorable, below 3.0 is ideal, and above 5.0 suggests elevated cardiovascular risk even when individual cholesterol values appear borderline. For example, a ratio of 3.3 means about 30% of your total cholesterol is protective HDL, while a ratio of 7.0 means only about 14% is HDL — a very different risk picture.
Your triglyceride/HDL ratio provides insight into insulin resistance and LDL particle character. A ratio below 2.0 suggests metabolically healthy lipid metabolism with predominantly large buoyant LDL. A ratio above 3.0 strongly predicts insulin resistance and small dense LDL particles — the most atherogenic form of LDL that is missed by standard LDL-C measurement. This explains why some people with 'normal' LDL still develop coronary artery disease.
Non-HDL cholesterol captures all atherogenic particles and is a secondary treatment target in ACC/AHA guidelines. Target non-HDL 30 mg/dL above your personalized LDL goal (e.g., if LDL target is <70 mg/dL, non-HDL should be <100 mg/dL).
Use this calculator when reviewing lipid panel results to get a complete picture of your cardiovascular lipid risk beyond the standard LDL number. It is particularly valuable when LDL appears borderline or normal but triglycerides are elevated and HDL is low — the pattern of atherogenic dyslipidemia associated with insulin resistance and metabolic syndrome.
Clinicians use cholesterol ratios in preventive cardiology to identify patients at elevated residual risk despite statin therapy, to screen for insulin resistance in at-risk populations (overweight, sedentary, family history of diabetes), and to monitor response to lifestyle interventions such as carbohydrate restriction or exercise programs.
For patients on statin therapy who have achieved their LDL goal, high TG/HDL ratio or non-HDL suggests additional interventions may be needed (omega-3 fatty acids, fibrates, lifestyle intensification).
Cholesterol ratios are supplementary tools, not replacements for comprehensive cardiovascular risk assessment. The 10-year ASCVD risk score and absolute LDL levels remain the primary metrics for treatment decisions in ACC/AHA guidelines. Ratios do not capture all risk modifiers: family history of premature coronary artery disease, coronary artery calcium score, elevated Lp(a), inflammatory conditions, and non-lipid risk factors (hypertension, diabetes, smoking) all contribute independently to cardiovascular risk.
The total/HDL ratio can be misleading in specific populations: very high HDL from rare genetic variants (CETP deficiency) may be dysfunctional despite favorable ratio. Very low total cholesterol from malnutrition or severe illness may also produce an artificially favorable ratio. Context always matters.
The TG/HDL ratio is a surrogate marker — it predicts insulin resistance and small dense LDL probability but does not directly measure them. Formal insulin resistance testing (HOMA-IR, euglycemic clamp), LDL particle size analysis, or apoB measurement provide more definitive information when clinically indicated.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Calculate LDL cholesterol from total cholesterol, HDL, and triglycerides using the Friedewald equation. Also reports non-HDL and total/HDL ratio.
CardiologyCalculate 10-year ASCVD risk using current 2026 ACC/AHA Pooled Cohort Equations. Statin thresholds: <5% low, 5–7.5% borderline, ≥7.5% intermediate, ≥20% high.
CardiologyCalculate your 10-year risk of cardiovascular disease using the Framingham Risk Score. Based on the landmark Framingham Heart Study data.
CardiologyClassify blood pressure readings into Normal, Elevated, Stage 1, Stage 2, or Hypertensive Crisis using ACC/AHA thresholds. Includes MAP and pulse pressure.